Brand Name for Fexofenadine
The brand name for fexofenadine is Allegra in the United States and Telfast in other countries 1, 2.
Available Formulations
Fexofenadine hydrochloride is marketed under these brand names and is available in multiple tablet strengths:
- 30 mg tablets
- 60 mg tablets
- 180 mg tablets
All formulations are film-coated tablets that can be identified by unique markings: 30 mg tablets have "03" on one side, 60 mg tablets have "06" on one side, and 180 mg tablets have "018" on one side 1.
Clinical Context
Fexofenadine is a second-generation, non-sedating H1-antihistamine used primarily for treating allergic rhinitis and urticaria 3, 4. What distinguishes this medication from other antihistamines is its complete lack of sedative properties even at doses higher than FDA-approved recommendations 3.
Key Clinical Advantages
No sedation at recommended or higher doses: Multiple studies confirm fexofenadine causes no sedation compared to placebo, unlike cetirizine or intranasal azelastine which may cause sedation at recommended doses 3.
No performance impairment: The medication does not cross the blood-brain barrier effectively, resulting in no cognitive or psychomotor impairment 3.
No anticholinergic effects: Unlike first-generation antihistamines, fexofenadine does not cause dry mouth, constipation, urinary retention, or increased risk of narrow-angle glaucoma 3.
Dosing
For allergic rhinitis, fexofenadine is available as once-daily dosing at 120 mg or 180 mg, which improves patient compliance compared to twice-daily regimens 2, 5. The 60 mg dose may be used twice daily as an alternative 4.